Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

NCT06232694 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
DRUG: Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
OTHER: utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]